In recent years, some novel mouse pancreatic cancer models (including orthotopic and heterotopic models) which can show more realistic features of human pancreatic cancer and contribute to the validation of drugs and targets with therapeutic potential in pancreatic cancer have been established by using different technical means.
- Skip to Main Content

Search withinThis JournalAnywhere

- Search term

- Search term

Login / Register

Editor-in-Chief: Fei Ma

Online ISSN:2770-9183

Print ISSN:2770-9191

Tsinghua University Press

Volume 3, Issue 5

October 2024

## Navigation Bar

### Menu

## Follow journal

Cancer Innovation is a high-quality, open access journal covering key topics in all aspects of cancer research, focusing on emerging interdisciplinary, strategic frontiers and key common technologies in oncology.

A new frontier in innovative oncology solutions. Cancer Innovation provides timely updates on advances and unmet needs, bringing innovative oncology solutions to life.

Presenting a unique combination of oncology research, innovation, and data. Cancer Innovation bridges the gap between biological, medical, engineering, computational and data sciences. Its integrated, multidisciplinary coverage supports progress from basic research to clinical translation.

A hub for collaboration and communication across disciplines. Cancer Innovation unites researchers and clinicians from diverse medical subspecialities, providing opportunities to exchange, collaborate, and explore together.

A high-quality platform for guidelines on clinical decisions. Led by the China National Cancer Center, the editors ensure authentic statistics, consensus, and guidelines for clinical reference. Cancer Innovation combines professional resources to close the shortcomings in the management of oncological comorbidities.

### News

We are glad to announce that Cancer Innovation has been indexed by Web of Science, Scopus, DOAJ, PMC (PubMed Center) and CAS: Chemical Abstract Service!

### Special issue call for papers

#### Onco-cardiology

Submission deadline: 30 April 2024

In-depth research on risk factors and interventions for cardiovascular diseases shared with tumors, cardiovascular complications caused by anti-tumor therapy, cardiac tumors and tumors combined with cardiovascular diseases are needed to improve the quality of life and prognosis of tumor patients. This special issue aims at collecting advanced Original Articles, Reviews, Meta-Analysis, Study Protocols, Clinical Guidelines, Technical Reports, Case Reports, Commentaries, News, and Editorials on onco-cardiology and related fields.

Guest editor: Professor Tong Liu, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University

Submission Site: ScholarOne System (please select for inclusion in 'Onco-cardiology')

For any inquiries about the appropriateness of contribution topics, please contact Prof. Tong Liu via [email protected]. If you need any assistance for submission, feel free to contact the Editorial Office via [email protected].

### Editors’ Choice

Treatment-induced cardiovascular toxicity is linked to ADT, VEGFR-TKIs, ICIs, and chemotherapy. We propose the new discipline of uro-cardio-oncology to address the relationship between cardiovascular disease and urological cancers. ADT, androgen deprivation therapy; ICI, immune checkpoint inhibitor; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.

Histone deacetylase (HDAC) inhibitor (HDACi) is a potent antitumor drug candidate for synovial sarcoma (SS) treatment. Twist1 expression often causes drug resistance. SN38 overcomes Twist1-induced drug resistance for HDACi through the suppression of Twist1 protein expression in SS cells.

### Editors’ Choice

This guideline has been developed by the Breast Cancer Expert Committee of the National Cancer Quality Control Center. The experts involved in this guideline have thoroughly examined the comprehensive management of bone health in breast cancer, aiming to establish a reference framework for managing bone health and standardizing the diagnosis and treatment of breast cancer patients.

This review discusses the vast valuable importance of Tumor microenvironment (TME) recapitulation in cancer research prioritizing individual roles of TME elements in the histopathology of cancer. Further, the review broadly describes of few of the recently developed 3D models that have their main focus restricted to drug development and their screening and/or implications of the approach in preclinical as well as translational research.

### Editors’ Choice

There is no consensus on the prognosis for patients with resectable colorectal liver metastasis (CRLM) who undergo simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy (NAC). We aim to construct the nomogram models to investigate the prognosis of patients with resectable CRLM undergoing simultaneous resection of primary and hepatic lesions without NAC.

There is no consensus on the prognosis for patients with resectable colorectal liver metastasis (CRLM) who undergo simultaneous resection of primary and hepatic lesions without neoadjuvant chemotherapy (NAC). We aim to construct the nomogram models to investigate the prognosis of patients with resectable CRLM undergoing simultaneous resection of primary and hepatic lesions without NAC.

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

### Editors’ Choice

The efficacy of programmed cell death-1/ligand 1 inhibitors in patients with advanced urothelial carcinoma is approximate to first-line platinum-based chemotherapy, and programmed cell death-1/ligand 1 inhibitors are safer than first- and second-line chemotherapy and have a broader prospect for use in combination therapy.

In this post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial, anlotinib demonstrated a potential survival benefit in small cell lung cancer (SCLC) with brain metastases (BM) compared with placebo, with manageable toxicity. Anlotinib significantly prolonged median progression-free survival (PFS) (hazard ratio [HR] = 0.15, 95% CI: 0.04–0.51; p = 0.0005) and median OS (HR = 0.26, 95% CI: 0.09–0.73; p = 0.0061) in SCLC patients with BM.

### Editors’ Choice



The tumor is one of the threats to children and adolescents' life and health, causing death and reduced quality of life. But there are few studies on them. Improving the survival rate and survival time of patients is our common goal. We reviewed the literature in recent years, and summarized the new progress achieved in terms of chemotherapy regimens, molecular targeted drugs, and immunotherapy, to provide new ideas for the treatment of tumors in children and adolescents.

### Editors’ Choice

A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients. We summarize the phase III clinical trial of target therapy and inmmunotherapy for glioblastoma and discuss the challenge faced contemporaneously and prospects of targeted drugs and immunotherapy in the future.

Lung adenocarcinoma (LUAD) patients with elevated breast cancer susceptibility gene 1 (BRCA1) expression had markedly worse overall survival and progression-free survival compared to those with reduced BRCA1 levels. In contrast, BRCA1 expression did not correlate with survival outcomes in squamous cell carcinoma patients. The overexpression of BRCA1 was an independent risk factor for LUAD and was indicative of an immune-suppressive tumor microenvironment.

### Editors’ Choice

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

## On the Cover

Editor's Choice:

This study demonstrates that circular RNAs (circRNAs) have great potential as biomarkers for cancer diagnosis and prognosis, which is highlighted by their detectability in tissues and fluid biopsy samples.

In recent years, some novel mouse pancreatic cancer models (including orthotopic and heterotopic models) which can show more realistic features of human pancreatic cancer and contribute to the validation of drugs and targets with therapeutic potential in pancreatic cancer have been established by using different technical means.

## Meet the Editor-in-Chief



Fei Ma , National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Fei Ma is the chief physician & director of Internal Therapy Center of Cancer Hospital, principal investigator of State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences. He has long been dedicated to basic, clinical and translational research in oncology, focusing on interdisciplinary studies. In the past 5 years, he has published more than 50 peer review papers as first/corresponding author, especially in Lancet Oncology, Journal of Clinical Oncology and Nature Communication.

## Why publish in Cancer Innovation?

- Your research will be free to access, making it available to read, download and share with ease.
- Quality and impactful research governed by an international and distinguished editorial board.
- Publish open access at no cost to you- fees are waived from 2022-2024.
- An official journal of the Boao Cancer Innovation Institute, devoted to innovative and significant research in basic research and clinical oncology, and published on behalf of Tsinghua University Press.
- Save time formatting your manuscript with free formatting submission.



Get the latest research from Cancer Innovation. Create a FREE Wiley Online Library account and register to receive Content Alerts today!

- Receive personalized alerts at a pace that suits you.
- Keep track of a paper of interest with citation alerts.
- Save content to easily manage your reading list.
- Save searches for instant review later.

#### Cancer Innovation adopts free format submission

With free format submission, you don’t need to worry about following formatting requirements during submission. We know your time is valuable and should be spent on your research, not re-typing reference lists.

## Articles

ORIGINAL ARTICLE

Open access

- First Published:  9 September 2024

### Graphical Abstract

Previous studies have confirmed the important role of Wnt family member 7B (Wnt7B) in the formation of various cancers such as breast, pancreatic, and gastric cancers; however, studies on the specificity of Wnt7B in tumors are limited to certain specific cancers, and systematic pan-cancer studies are lacking, and whether it can be used as a potential biomarker for cancer diagnosis and prognosis remains to be determined. We used bioinformatics techniques and immunohistochemistry (IHC) to observe its expression and function in cancerous and paracancerous tissues of various tumors. Finally, we found that Wnt7B exhibited significant upregulation in the majority of cancer cases，at the same time，Wnt7B affects cancer prognosis through regulating tumor microenvironment，immune infiltration, tumor stemness, and other aspects, which suggests that Wnt7B can be a new cancer prognostic indicator and therapeutic target, and also the pharmacosensitivity analysis related to Wnt7B and cancer therapy can provide some help for clinical precision treatment.

CLINICAL GUIDELINE

Open access

- First Published:  30 July 2024

### Graphical Abstract

Patient-centered care (PCC) is a developing and innovative approach to the diagnosis and treatment of malignant tumors, aiming to improve the experience of cancer patients throughout their disease management. This consensus provides a clear definition of PCC, outlines its main components as observed in real-world practice, delves into the implementation of PCC, and explores its potential benefits.

REVIEW

Open access

- First Published:  3 July 2024

### Graphical Abstract

This systematic review is carried out using the preferred reporting items on systematic reviews and meta-analysis (PRISMA) guideline in three steps as follows:

- Step 1:
  Identifying studies (total of 193 studies were initially included).

- Step 2:
  Selecting the studies (total of 30 articles met the inclusion criteria for our comprehensive review).

- Step 3:
  Data extraction and summarization (A data extraction form was developed in Google Sheets, consisting of eight variables, including Authors, Year, the aim of the study (Objective), Data set(s), Data type, Important features, type of artificial intelligence (machine learning or deep learning), and the Explained model. Two reviewers (Amirehsan Ghasemi and Soheil Hashtarkhani) extracted data from all included articles, and any disagreement was resolved by consensus.

- Abstract

- Full text

- PDF

- References

- Request permissions

ORIGINAL ARTICLE

Open access

- First Published:  28 June 2024

### Graphical Abstract

Information from 187 patients with neuroblastoma were retrospectively collected and randomly divided into the training and validation sets. Radiomics features were extracted from computed tomography to build noninvasive radiomics models. We attempted 13 machine learning algorithms and eventually chose three best-performed models.

ORIGINAL ARTICLE

Open access

- First Published:  5 June 2024

### Graphical Abstract

Clinical studies showed that atherosclerotic cardiovascular disease (ASCVD) and cancer often coexist in the same individual. The study first showed that obesity could promote atherosclerosis burden as well as promote tumorigenesis and metastasis of lung cancer in the same individual mice. The results showed that obesity could contribute to the coexistence of atherosclerosis and lung cancer; so, screening both ASCVD and lung cancer would be significant in obese patients. LOX-1-related pathway likely was a significant contributor to the coexistence of atherosclerosis and lung cancer in the same individual. LOX-1 could be a target for the management of ASCVD and lung cancer in obese patients.

Articles with the most citations published in the Last 2 Years according to CrossRef.
The citation counts listed reflect the total number of all citations to date.

ORIGINAL ARTICLE

Open access

### Graphical Abstract

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.

REVIEW

Open access

### Graphical Abstract

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

REVIEW

Open access

### Graphical Abstract

- Primary or local tumor ablation following local therapy (such as radiotherapy, photodynamic therapy, and cryoablation) causes the release of damage-associated molecular proteins and tumor-associated antigens, which are then presented to dendritic cells (antigen-presenting cells) and results in the development of a systemic antitumor immune response, or “abscopal effect.”

- However, the immune-suppressive tumor microenvironment blocks the antitumor immune response through several mechanisms, including the immune checkpoint mechanism (programmed death-1, programmed death ligand-1, and cytotoxic T lymphocyte-associated protein-4) and the overexpression of immunosuppressive cells myeloid-derived T-regulatory cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and so on.

- The use of immunotherapy can be used to treat these immune suppression mechanisms. Therefore, local therapy and immunotherapy combined have been proven to provide an effective abscopal impact. Immune-related adverse effects, however, can result from immunotherapy. Determining the precise sort of immunosuppressive mechanism and using specialized immunotherapy can combat these drawbacks. This can be achieved by using a nanotheranostic method, in which nanoparticles are loaded with prognostic biomarkers and predictive biomarkers, and to develop a strategy that could be multifaceted and address all potential obstacles that slow the abscopal impact.

- Abstract

- Full text

- PDF

- References

- Request permissions

REVIEW

Open access

### Graphical Abstract

This study demonstrates that circular RNAs (circRNAs) have great potential as biomarkers for cancer diagnosis and prognosis, which is highlighted by their detectability in tissues and fluid biopsy samples. CircRNAs may act as biomarkers in cancers including glioma, bladder cancer, breast cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer, lung cancer, kidney cancer, pancreatic cancer, and leukemia.

REVIEW

Open access

### Graphical Abstract

The two most frequent alterations in nonsmall cell lung cancer patients were epidermal growth factor receptor and KRAS mutations, accounting for 10%–40% and 25%–32%, respectively. Although the incidence rate is relatively low, other gene mutations including anaplastic lymphoma kinase fusion, MET ex14+, ROS1 fusion, KRAS mutation, and so forth, are also crucial to the survival of patients, and numerous significant pharmacological advances have been produced so far.

REVIEW

Open access

### Graphical Abstract

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

REVIEW

Open access

### Graphical Abstract

This review summarizes the applications of digital medicine in cancer prevention, screening, diagnosis, and treatment, as well as clinical trials. Integrating digital medicine into clinical practice has the advantages of broader applicability, greater cost-effectiveness, better accessibility, and improved diagnostic and therapeutic performance.

ORIGINAL ARTICLE

Open access

### Graphical Abstract

C5AR2 in not only a prognostic biomarker, but also may play a key role in controlling tumor immune microenvironment in gliomas. These findings suggest that C5AR2 is a potential prognostic marker and immunotherapeutic target in glioma.

ORIGINAL ARTICLE

Open access

### Graphical Abstract

LHXs are potential and unique diagnostic and prognostic markers in BRCA, and possibly participate in the development and progression of BRCA in different manners through various signaling pathways and/or regulatory mechanisms.

ORIGINAL ARTICLE

Open access

### Graphical Abstract

Both SLC16A1 and SLC16A3 expression were increased in LGG and GBM. GO analysis indicated that SLC16A1 was related to Herpes simplex virus 1 infection while SLC16A3 was involved in neutrophil activation. SLC16A3 as well as SLC16A1 were closely related to immune infiltration and checkpoints LGG and GBM.

The most read articles published in the Last 2 Years

REVIEW

Open access

### Graphical Abstract

Three dimensional (3D) culture is a promising model for tumor research, replicating solid tumor characteristics. Advantages include high throughput and retention of heterogeneity. Traditional matrigel-submerged organoid culture requires exogenous cells to study the tumor microenvironment (TME). A holistic approach using patient-derived tumor fragments (PDTFs), air-liquid interface (ALI), suspension 3D culture, and microfluidic tumor-on-chip (ToC) models better mimic the tumor structure and composition. Organoid co-culture models are useful for studying the TME, immunotherapy, biomarkers, drug screening, and infections. These 3D systems aim to improve therapeutic approaches and patient outcomes.

REVIEW

Open access

### Graphical Abstract

This article summarizes the annual progress of breast cancer chemotherapy, targeted therapy, endocrine therapy and immunotherapy in 2022, providing valuable information for future research to better guide individualized treatment of breast cancer, thereby improving the prognosis and quality of life of breast cancer patients.

REVIEW

Open access

### Graphical Abstract

The age-standardized cancer incidence rate data for the selected countries indicate a great areal variation and different global trends for each type of cancer. Analysis of the worldwide statistical data regionally for cancer incidence rates for certain cancers meaningfully correlate with diet, lifestyle, and environmental factors.

REVIEW

Open access

### Graphical Abstract

A wide variety of targeted drugs and immunotherapies are tested for patients with glioblastoma, but not all of these drugs are effective, and only a few of these trials have prolonged the lives of patients. We summarize the phase III clinical trial of target therapy and inmmunotherapy for glioblastoma and discuss the challenge faced contemporaneously and prospects of targeted drugs and immunotherapy in the future.

REVIEW

Open access

### Graphical Abstract

In recent years, immunotherapy has gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

REVIEW

Open access

### Graphical Abstract

This review discusses the vast valuable importance of Tumor microenvironment (TME) recapitulation in cancer research prioritizing individual roles of TME elements in the histopathology of cancer. Further, the review broadly describes of few of the recently developed 3D models that have their main focus restricted to drug development and their screening and/or implications of the approach in preclinical as well as translational research.

CLINICAL GUIDELINE

Open access

### Graphical Abstract

This guideline has been developed by the Breast Cancer Expert Committee of the National Cancer Quality Control Center. The experts involved in this guideline have thoroughly examined the comprehensive management of bone health in breast cancer, aiming to establish a reference framework for managing bone health and standardizing the diagnosis and treatment of breast cancer patients.

REVIEW

Open access

### Graphical Abstract

This review summarizes the applications of digital medicine in cancer prevention, screening, diagnosis, and treatment, as well as clinical trials. Integrating digital medicine into clinical practice has the advantages of broader applicability, greater cost-effectiveness, better accessibility, and improved diagnostic and therapeutic performance.

ORIGINAL ARTICLE

Open access

### Graphical Abstract

A novel health system reliability method has been developed and applied to cardio and cancer death rate data. Accurate disease multiregional prediction is done.

REVIEW

Open access

### Graphical Abstract

- Primary or local tumor ablation following local therapy (such as radiotherapy, photodynamic therapy, and cryoablation) causes the release of damage-associated molecular proteins and tumor-associated antigens, which are then presented to dendritic cells (antigen-presenting cells) and results in the development of a systemic antitumor immune response, or “abscopal effect.”

- However, the immune-suppressive tumor microenvironment blocks the antitumor immune response through several mechanisms, including the immune checkpoint mechanism (programmed death-1, programmed death ligand-1, and cytotoxic T lymphocyte-associated protein-4) and the overexpression of immunosuppressive cells myeloid-derived T-regulatory cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and so on.

- The use of immunotherapy can be used to treat these immune suppression mechanisms. Therefore, local therapy and immunotherapy combined have been proven to provide an effective abscopal impact. Immune-related adverse effects, however, can result from immunotherapy. Determining the precise sort of immunosuppressive mechanism and using specialized immunotherapy can combat these drawbacks. This can be achieved by using a nanotheranostic method, in which nanoparticles are loaded with prognostic biomarkers and predictive biomarkers, and to develop a strategy that could be multifaceted and address all potential obstacles that slow the abscopal impact.

- Abstract

- Full text

- PDF

- References

- Request permissions

## Latest news

## Recent issues

October 2024

August 2024

June 2024

April 2024

### Sign up for email alerts

Enter your email to receive alerts when new articles and issues are published.

Email address*

Please select your location and accept the terms of use.

Country or location*

Open this select menuAfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua And BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius And SabaBosnia And HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic Of TheCook IslandsCosta RicaCôte D'ivoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-bissauGuyanaHaitiHeard Island And Mcdonald IslandsHoly See (vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic OfIraqIrelandIsle Of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic OfKorea, Republic OfKosovo, Republic OfKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic OfMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesia, Federated States OfMoldova, Republic OfMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNetherlands AntillesNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian Territory, OccupiedPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarReunionRomaniaRussian FederationRwandaSaint BarthélemySaint HelenaSaint Kitts And NevisSaint LuciaSaint MartinSaint Pierre And MiquelonSaint Vincent And The GrenadinesSamoaSan MarinoSao Tome And PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia And The South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard And Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic OfThailandTimor-lesteTogoTokelauTongaTrinidad And TobagoTunisiaTürkiyeTurkmenistanTurks And Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic OfViet NamVirgin Islands, BritishVirgin Islands, U.s.Wallis And FutunaWestern SaharaYemenZambiaZimbabwe

I consent to Wiley Online Library’s
Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy. _*_I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers,

newsletter & promotions from Wiley.
See Privacy Policy for more details.

Sign up to alerts

Continue

## Tools

### Peer-Review Metrics

- Submission to first decision: 32
- Submission to final decision: 58
- Submission to acceptance: 65

\* Median number of days in 2023

An official journal of Boao Cancer Innovation Institue, published on behalf of Tsinghua University Press.



## More from this journal

2770-9183.glioblastoma)

##### Understanding Open Access

As an open access journal, all articles in Cancer Innovation are freely available to read, download and share immediately on publication. Learn more about open access:

## More TUP journals

August 2024

August 2024

Issue Edited by:

Bo Gao, Danny JJ Wang

June 2024

June 2024

## Relevant OA journals

June 2024

August 2024

September 2024

September 2024

September 2024

September 2024

September 2024

June 2024

September 2024

# Journal list menu

- Journal

-  Articles

- Actions

## Tools

## Follow journal

## Additional links

### About Wiley Online Library

### Help & Support

### Opportunities

### Connect with Wiley

Copyright © 1999-2024 John Wiley & Sons, Inc or related companies. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.



## Log in to Wiley Online Library

Email or Customer ID

Password



## Change Password

Old Password

New Password

Too ShortWeakMediumStrongVery StrongToo Long

#### Your password must have 10 characters or more:

- a lower case character,
- an upper case character,
- a special character
- or a digit

Too Short

## Password Changed Successfully

Your password has been changed

## Create a new account

Email



## Forgot your password?

Enter your email address below.

Email

Please check your email for instructions on resetting your password.
If you do not receive an email within 10 minutes, your email address may not be registered,
and you may need to create a new Wiley Online Library account.

## Request Username

Can't sign in? Forgot your username?

Enter your email address below and we will send you your username

Email

Close

If the address matches an existing account you will receive an email with instructions to retrieve your username